Stem Cell Clinic

Thanyapura, StemCells21 to offer premium stem cell treatments in Thailand – BSA bureau

The partnership will offer premium stem cell treatments for various degenerative diseases, immune disorders, injuries and anti-ageing.

Thanyapura Sports and Health Resort, Phuket has partnered with StemCells21 (SC21), a medical biotech company based in Bangkok, Thailand. With over a decade of clinical history and 100 years of collective team experience, SC21 combines 21stcentury cellular medicine and cutting-edge supportive therapies to offer the highest quality stem cell treatments with Mesenchymal Stem Cells (MSCs) and Induced Pluripotent Stem Cells (iPSCs).

A first of its kind for Phuket, Thanyapura in partnership with SC21, will offer premium stem cell treatments for various degenerative diseases, immune disorders, injuries and anti-ageing. The treatments can also tackle a host of medical problems such as type 2 diabetes, osteoarthritis, chronic back pain and inflammatory lung diseases such as asthma and bronchitis, as well as strengthen body immunity and improve fertility.

In the sporting world, regenerative medicine is seen as a crucial component and can aid in optimising the human body to perform at a higher level, as well as being highly effective in the treatment of sports injuries through faster healing, reduced injury inflammation and the regeneration of injured tissue. The human-based regenerative therapy has been successful with high calibre athletes for endurance enhancement and lengthening professional careers by reducing injury rates.

Guests can book a free dedicated one-on-one consultation with a certified stem cell specialist for their first session. Those seeking longer-term treatments can book a discounted stay at Thanyapura to utilise its world-class facilities, award-winning vegan and vegetarian restaurants and lifestyle clinic.Team isexcited to facilitate their first clinic outside of Bangkok.

President & CEO of Thanyapura World, Philipp Graf von Hardenberg said, "Treatment packages can be customised from the number of Premium Grade (P1) MSCs to the treatment duration and include supportive therapies from a comprehensive health check-up to the highest standards of after-care services. Thanyapuras 360 approach will help in delivering better, longer-lasting outcomes for challenging conditions that conventional therapies often fail to address, such as stopping disease progression, as well as avoiding surgical intervention.

Go here to see the original:
Thanyapura, StemCells21 to offer premium stem cell treatments in Thailand - BSA bureau

Neurons stripped of their identity are hallmark of Alzheimer’s disease, study finds – National Science Foundation

Changes in the structure of chromatin hold new answers

Neurons stripped of their identity are hallmarks of Alzheimer's disease, researchers have found.

November 18, 2020

Researchers at the University of California San Diego have identified new Alzheimer's disease mechanisms in neurons. The scientists have discovered that changes in the structure of chromatin, a tightly coiled form of DNA, trigger neurons to lose their specialized function and revert to an earlier cell state. That results in the loss of synaptic connections, an effect associated with memory loss and dementia.

The U.S. National Science Foundation-funded findings are published in Science Advances.

The study was founded on the question: How do neurons in patients with Alzheimer's disease differ from neurons in healthy individuals?

"It's a fundamental question that would provide the framework and foundation for understanding Alzheimer's disease at the cellular level, and pave the path for novel therapeutic approaches," said bioengineer Shankar Subramaniam.

Subramaniam worked with an interdisciplinary team of engineers and neuroscientists at UC San Diego to answer this question. They started by taking human induced pluripotent stem cells derived from patients with familial Alzheimer's disease, a hereditary form of Alzheimer's, and transformed them into neurons.

The scientists then used next-generation sequencing techniques to look at which genes are being expressed in the neurons and how gene expression is regulated, then compared how they differ in the neurons of healthy individuals.

The bioengineers discovered that neurons derived from the affected patients revert to a precursor state. "In other words, they cease to be neurons," Subramaniam said. "This is the key defect observed across a diversity of patients with distinct mutations. The consequences to the brain are dramatic, with loss of synaptic connections leading to cognitive decline."

The researchers traced all the mechanisms to changes in the structure of chromatin. Parts of this structure consist of open regions, where genes are expressed or regulated, and other parts consist of closed regions, where gene expression is repressed. In the diseased neurons, some regions that were open became closed, and vice versa. As a consequence, the neurons are not behaving as they should be, Subramaniam explained.

The team is now working on developing drugs to inhibit these mechanisms.

"The lessons gleaned from examining large-scale connectivity have fascinating implications beyond communication networks, including brain connectivity in neural studies, with the potential to impact the quality of life," said Phil Regalia, a program director in NSF's Directorate for Computer and Information Science and Engineering.

Read more from the original source:
Neurons stripped of their identity are hallmark of Alzheimer's disease, study finds - National Science Foundation

Fred Hutch at ASH: Fauci fireside chat, latest on cell therapies, repairing immune function, COVID and clots and more – Newswise

Newswise SEATTLE Nov. 18, 2020 Fred Hutchinson Cancer Research Centers latest findings on cell therapies, repairing immune function, and more will be featured at the 62nd American Society of Hematology Annual Meeting & Exposition, to be held virtually Dec. 5 8.

Dr. Stephanie Lee, ASH president and Fred Hutch physician-scientist will kick off the meeting with a fireside chat with Dr. Anthony Fauci. She will also chair ASHs annual E. Donnall Thomas Lecture, named for the Hutchs Nobel laureate Dr. Thomas, who would have turned 100 this year. This lectureship recognizes pioneering research achievements.

Lee shared other meeting highlights:

Follow Lee on Twitter: @StephanieLeeMD.

See below for selected presentations by Fred Hutch researchers, along with Fred Hutch experts to follow on Twitter. Presentations times are in the Pacific time zone.

REPAIRING IMMUNE FUNCTION

Damage-Induced Pyroptotic Cell Death Facilitates Regeneration of the Thymus

As a small but mighty butterfly shaped gland in the chest, the thymus is the training ground for T cells to mature into disease-killing machines in the body. But over time, the thymus wears out from stress, infection and age. Finding ways to help repair it could have broad implications for preventing and treating cancer. Dr. Sinead Kinsella, a researcher in the lab of Dr. Jarrod Dudakov, will present findings on a new way of thymus regeneration in which a cell death process called pyroptosis is critical in releasing large numbers of signaling molecules that can trigger the thymus to repair itself. Abstract No. 735 (oral presentation) Monday, Dec. 7, 2020: 2:45 p.m. On Twitter: Dr. Sinead Kinsella: @shinkinsella Dr. Jarrod Dudakov: @Dudakov_lab

T CELL RECEPTOR THERAPY

The immune system plays a key role in detecting tumor antigens and killing cancer cells. But immune response to tumor antigens varies and is often insufficient to prevent tumor growth and relapse. Fred Hutch physician-scientists have identified specific tumor antigens that can be targeted to trigger a potent immune response. The team is creating immunotherapy using genetically modified T cells, called TCR T-cell immunotherapy, to augment these responses in patients.

Phase I Study of Adoptive Immunotherapy with HA-1-Specific CD8+ and CD4+ Memory T Cells for Children and Adults with Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation (HCT): Trial in Progress Dr. Elizabeth Krakowwill present a Phase I trial in progress. It uses a T-cell receptor therapy developed byDr. Marie Bleakleyto treat adult and pediatric patients who have relapsed after receiving a stem cell (blood and marrow) transplant for leukemia or other related conditions. Abstract No. 492 (oral presentation) Sunday, Dec. 6, 2020: 2:15 p.m.

A d SF3B1 Neoantigen Is Presented on Primary Malignant Cells and Induced Pluripotent Stem Cell-Derived Hematopoietic Lines

Neoantigens, tiny markers that arise from cancer mutations, flag cells as cancerous and could lead to more targeted precision immunotherapies. But, because hundreds of mutations exist on a tumor, targeting the right neoantigen is crucial to trigger an immune response. Dr. Melinda Biernacki, working with the Hutchs Dr. Marie Bleakley, will present findings that identify a specific neoantigen, SF3B1, present in Myelodysplastic Syndromes (MDS), secondary acute myeloid leukemia (AML) and advanced chronic lymphocytic leukemia (CLL), as a promising target for treatment with immunotherapy. Abstract No. 3265 (poster presentation) Monday, Dec. 7, 2020, 7:00 a.m. 3:30 p.m.

CD19 CAR T-CELL THERAPY

Hutch scientists continue to take deep dives into understanding how CD19 CAR T-cell therapy works and how to make it work better for more patients.

Age, performance status, and comorbidities in relation to IEC-associated toxicities (including ICANS) followed by live Q&A panel discussion Scientific Workshop Thursday, Dec. 3, 2020, 2:45 p.m. 3:17 p.m. To be presented by Jordan Gauthier, MD On Twitter: Dr. Jordan Gauthier: @drjgauthier

High IL-15 Serum Concentrations Are Associated with Response to CD19 CAR T-Cell Therapy and Robust In Vivo CAR T-Cell Kinetics Findings by Dr. Jordan Gauthier, a clinician-scholar at Fred Hutch, suggest that high levels of IL-15 could improve CD19 CAR T-cell efficacy and in vivo persistence. Abstract No. 1442 (poster presentation) Saturday, Dec. 5, 2020, 7:00 a.m. 3:30 p.m. ASH Virtual Poster Walk Thursday, Dec. 10, 2020, 7 a.m. On Twitter: Dr. Jordan Gauthier: @drjgauthier

Patient-Reported Outcomes at Time of CAR-T Cell Therapy Abstract No. 3485 (poster presentation) Monday, Dec. 7, 2020, 7:00 a.m. 3:30 p.m. To be presented by Erin Mullane, DNP

CD20 CAR T-CELL THERAPY

Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Researchers at Fred Hutch have developed a CAR T-cell therapy targeting CD20, a specific protein marker in blood cancers, for treating patients with B-cell non-Hodgkin lymphoma who have relapsed or previously been non-responsive to treatment. Dr. Mazyar Shadman will early results from the ongoing trial taking place at the Seattle Cancer Care Alliance, the Hutchs clinical-care partner. Abstract No. 1443 (poster presentation) Saturday, Dec. 5, 2020, 7:00 a.m. 3:30 p.m. On Twitter: Dr. Mazyar Shadman: @mshadman

CAR T for AML

Therapeutic Targeting of Mesothelin in Acute Myeloid Leukemia with Chimeric Antigen Receptor T Cell Therapy Abstract No. 1959 (poster presentation) Sunday, Dec. 6, 2020, 7:00 a.m. 3:30 p.m. To be presented by Quy Le, PhD

MORE CELL THERAPY

Challenges in Cell Therapy: Relapse and Toxicities Live Q&A Even as a growing number of cancer patients benefit from advances in immunotherapy, relapse and toxic side effects from the treatment remain challenging. Dr. Aude Chapuis will discuss new strategies using genetically modified immune cells to improve the next generation of adoptive T cell therapies in the treatment of solid tumor and blood cancers. Scientific Program, Live Q&A Saturday, December 5, 2020, 9:30 a.m. 10:15 a.m.

PRECISION MEDICINE AND AML

Researchers from the lab ofDr. Soheil Meshinchi, a pediatric oncologist and acute myeloid leukemia specialist, are mapping genetic mutations to how well a patient will respond to various treatments. Their presentations show that ongoing genomic profiling work can help guide targeted treatments for patients with AML, which is the deadliest leukemia among children and young adults.

Genome and Transcriptome Profiling of Monosomy 7 AML Defines Novel Risk and Therapeutic Cohorts Abstract No. 274, (oral presentation) Saturday, Dec. 5, 2020, 2:30 p.m. To be presented by Rhonda E. Ries, MA

Clinical Benefit and Tolerability of Crenolanib in Children with Relapsed Acute Myeloid Leukemia Harboring Treatment Resistant FLT3 ITD and Variant FLT3 TKD Mutations Treated on Compassionate Access Abstract No. 1973, (poster presentation) Sunday, December 6, 2020, 7:00 a.m. 3:30 p.m. To be presented by Katherine Tarlock, MD

Mesothelin Expression Is Associated with Extramedullary Disease and PromotesIn VivoLeukemic Growth in Acute Myeloid Leukemia Abstract No. 1993, (poster presentation) Sunday, Dec. 6, 2020, 7:00 a.m. 3:30 p.m. To be presented by Katherine Tarlock, MD

Target-Informed Repurposing of Immunotherapies in AML a Transcriptome Based Approach for Identifying Immediately Available Therapeutics Abstract No. 2003, (poster presentation) Sunday, Dec. 6, 2020, 7:00 a.m. 3:30 p.m. To be presented by Amanda R. Leonti, MS

BLOOD CLOTS AND CANCER, COVID-19

Dr. Gary Lyman, a medical oncologist, hematologist and public health researcher, has helped develop treatment guidelines for managing blood clots in cancer patients and more recently in COVID-19 patients. His colleagues will present on the COVID-19 findings at this years ASH. Dr. Lyman is available to speak with media. On Twitter: Dr. Gary Lyman: @gary_lyman

Severity of Sars-Cov-2 Infection in Patients with Hematologic Malignancies: A COVID-19 and Cancer Consortium (CCC19) Registry Analysis Abstract No. 1632 (poster presentation) Saturday, Dec. 5, 2020, 7:00 a.m. 3:30 p.m.

Incidence of and Risk Factors for Venous Thromboembolism Among Hospitalized Patients with Cancer and COVID-19: Report from the COVID-19 and Cancer Consortium (CCC19) Registry Abstract No. 204; Session No. 701 (oral presentation) Monday, Dec. 7, 2020: 2:45 PM

HEALTHCARE ECONOMICS

Comparison of Outcomes and Utilization of Therapy in Multiple Myeloma Patients in the USA and Alberta, Canada Abstract No. 2516 (poster presentation) Sunday, Dec. 6, 2020, 7:00 a.m. 3:00 p.m. To be presented by Andrew J. Cowan, MD On Twitter: Dr. Andrew Cowan: @andrewcowanmd Co-author Dr. Veena Shankaran: @ShankaranVeena

CELL BIOLOGY

Distinct Transcriptional signatures distinguish the emergence of multipotent progenitors and hematopoietic stem cells from endothelial precursors in the murine embryo Abstract No. 908, (poster presentation) Saturday, Dec. 5, 2020, 7:00 a.m. 3:30 p.m. To be presented by Tessa Dignum, BS

Note: Scientists at Fred Hutch played a role in developing these discoveries, and Fred Hutch and certain of its scientists may benefit financially from this work in the future.

###

At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutchs pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nations first National Cancer Institute-funded cancer prevention research program, as well as the clinical coordinating center of the Womens Health Initiative and the international headquarters of the HIV Vaccine Trials Network.

See more here:
Fred Hutch at ASH: Fauci fireside chat, latest on cell therapies, repairing immune function, COVID and clots and more - Newswise

Stem Cells Market Value Expected To Reach $17.79 Billion By 2027 – Eurowire

Precedence Research published comprehensive research on the Stem Cells Market, which provides business strategies, research & development activities, a concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape, and regional proliferation of this industry.

The global Stem Cells Market size worth around US$ 17.79 Billion by 2027 and is expected to grow at a CAGR of 8.61% during the forecast period 2020 to 2027. The report offers an analysis of the global Stem Cells Market for the period 2016 to 2027, wherein 2020 to 2027 is the forecast period and 2019 is considered as the base year.

The Global Stem Cells Market explores the current outlook of the whole market. This report provides a comprehensive and insightful preface of the market, Revenues by players, Revenues by regions, market with value chain structure, Average prices, Competitive landscape, policy study, Dynamics analysis using admissible tools and techniques, market target segmentation and industry trends and developments during the forecast period 2020-2027.

This is the latest report, covering the current COVID-19 impact on various factors of market such as Future Analysis, Business Opportunities, Supply-Demand Analysis, Investment, Revenue and Cost Analysis by Key Companies 2027. The pandemic of Coronavirus (COVID-19) has affected not only health but every aspect of life globally. The rapidly changing market scenario and initial and future assessment of the impact are covered in the report.

The Final Report will cover the impact analysis of COVID-19.

Request Coronavirus Impact Analysis on This [emailprotected]https://www.precedenceresearch.com/sample/1118

Years Covered in the Study:

Objectives of this report:

Get Customization on this Research [emailprotected]https://www.precedenceresearch.com/customization/1118

Key Players:

The Stem Cells Market is consolidated with major number of manufacturers. The company profiling of key players in the market includes major business strategies, company overview and revenues. In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report. Primary research represents a bulk of research efforts, supplemented by extensive secondary research.

Some of the significant players in the Stem Cells Market include:

Market Segmentation:

Segments Covered in the Report

This research report estimates revenue growth at global, regional, and country levels and offers an analysis of present industry trends in every sub-segment from 2016 to 2027. This research study analyzes the market thoroughly by classifying global Stem Cells Market report based on different parameters including type and region:

By Product

By Application

By Technology

By Therapy

By Regional Outlook

Key Questions Answered:

The Final Report will cover the impact analysis of COVID-19.

Download Full Study [emailprotected] https://www.precedenceresearch.com/checkout/1118

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call:+1 774 402 6168

Email:[emailprotected]

Follow us on LinkedIn

Link:
Stem Cells Market Value Expected To Reach $17.79 Billion By 2027 - Eurowire

How regenerative medicine could be used to contain COVID-19, others – Guardian

*Practice provides answer to challenges conventional medicine deemed unfixable, say experts More studies are validating the use of regenerative medicine to restore damaged organs, restore acute stroke patients, heal chronic pain and erectile dysfunction in male and female as well as prevent and treat viral infections such as COVID-19.

Indeed, several studies have shown that regenerative medicine is uniquely positioned to provide advanced organoid models to understand the infection mechanism of, identify patients at risk for, and develop ways to prevent COVID-19, as well as to introduce innovative treatments that have immune-modulatory and regenerative properties.

Organoids are tiny, self-organised three-dimensional tissue cultures that are derived from stem cells. Such cultures can be crafted to replicate much of the complexity of an organ, or to express selected aspects of it like producing only certain types of cells.

According to a recent study published in the journal Stem Cell Reviews and Reports and titled Regenerative Medicine in COVID-19 Treatment: Real Opportunities and Range of Promises, studies are increasing to find the best therapeutic approach for COVID-19 and its management.

The researchers said regenerative medicine offers various cell-tissue therapeutics and related products, such as stem cell therapy, natural killer (NK) cell therapy, Chimeric antigen receptor (CAR) T cell therapy, exosomes, and tissue products. Interestingly, mesenchymal stem cells (MSCs) can reduce inflammatory symptoms and protect against cytokine storm, which critically contributes to the COVID-19 progression, they said.

The researchers concluded: COVID-19 can involve multiple systems, including the central nervous system, the gastrointestinal system, and the respiratory system, and this will depend on its profound effects on the immune system. Regenerative medicine offers various cell-tissue therapeutics and related products that might help the reversal of COVID-19-related immune dysregulation. In particular, the promising features of MSCs, including their regenerative properties and ability to differentiate into diverse cell lineages, have generated considerable interest among researchers whose work has offered intriguing perspectives on cell-based therapies for various diseases.

The immune-modulatory effects of MSCs, which may assist in inhibiting cytokine storm and lung inflammation, are of particular interest for COVID-19 therapy. Finally, Induced pluripotent stem cells (iPSCs) can help the development of a personalised approach to COVID-19 therapy.

iPSCs are useful for researchers as they can provide an inexhaustible supply of cells that are identical to the patients.

A United States (U.S.) Board Certified Internist with a strong passion for regenerative aesthetic and cosmetic medicine, and Medical Director of Glory Wellness & Regenerative Centre, Ikeja, Lagos, Dr. David Ikudayisi, told The Guardian: One of the regenerative medicine protocols, which we also have available at our Centre, was approved for COVID-19 purposes; leveraging its immune modulatory effect to calm the potentially fatal cytokine storm of the disease. It also has the benefit of preventing or limiting lung scarring. Another protocol is in the early phase of clinical trial. While we are not a COVID-19 treating centre, it is important to note that regenerative medicine can play a role in the reduction of many of the adverse effects caused by COVID-19.

Ikudayisi said the future of regenerative medicine is very bright. We believe that the future of regenerative medicine is inevitable, and that conventional medicine will only have to catch up as it usually does to new discoveries in medicine. The more people get to hear about the merits and see the evidence; it will not be long before it becomes the norm. It starts with everyday people and medical professionals doing their due diligence and doing their research as I did. My team and I are always available to answer questions about it, and we welcome it on all our social platforms as well. We really hope it catches up soon enough to maximise these great benefits for many more patients in dire need of these amazing solutions.

Regenerative medicine has continued to generate excitement. What makes it significantly different from conventional medicine, and why would you recommend it for anyone in need of treatment? Ikudayisi said: It is great to see that Nigeria is catching up with the possibilities of regenerative medicine for our health. Conventional medicine uses anything from conservative management, the use of medication, or surgery at the other extreme to help maintain good health or get us as close to it as possible.

He said regenerative medicine on the other hand leverages the bodys natural healing mechanisms and attempts to accentuate their effects by increasing their availability to the specific organs needing regeneration. The ability to harness the bodys natural healing mechanisms using adult stem cell therapy (a subcategory of regenerative medicine) while minimising adverse effects confers on regenerative medicine a considerably greater safety profile than conventional medicine, Ikudayisi said.

He said regenerative medicine is not the secret sauce to fix all health problems, but is, however, a great tool provided by modern medicine to provide an answer to many health challenges that conventional medicine had deemed unfixable. Ikudayisi said conditions that have been considered incurable by conventional medicine due to their degenerative effects, are now made curable in the practical sense as regenerative medicine takes care of the organ degeneration.

The physician said the scientific/physiological base of the therapeutic effects of regenerative medicine, specifically adult stem cell therapy, creates endless opportunities for its application. Think about it this way, if the medical condition is of a degenerative nature, then regenerative medicine can be a viable option, he said.

Ikudayisi said he would continue to recommend regenerative medicine to anyone in need of treatment because where conventional medicine fails; it offers hope and delivers results beyond what conventional medicine can offer in most cases. The benefits are even more noticeable in acute phases of degeneration, he said.

Can regenerative medicine treat only select ailments or all manner of sicknesses? Ikudayisi said: The scope of application is broad and multi-systemic. This means it can be used for various systems and functions in the body. While the exceptions are diseases of a non-degenerative nature such as genetic or chromosome-related diseases; nonetheless, people with these challenges can see a reduction or improvement in symptoms even though it is not cured. Healthy people use it for anti-agEing, to feel stronger and healthier as well as look younger as they age.

As I mentioned earlier, regenerative medicine is not here to replace other branches of medicine. Like other new innovations in medicine, it can add value to other forms of medicine. For example, a patient with a displaced fracture needs the intervention of an orthopedic surgeon not regenerative medicine. However, it can be added during or after the orthopedic surgery to accelerate the healing process.

Here at Glory Wellness & Regenerative Centre in Lagos, Nigeria, we have seen so many success stories with this branch of medicine. We have treated patients with complex quadriplegia (two years old injury before our involvement due to partial transection of cervical spinal cord) and another with over nine years with cerebral palsy, both of whom have now gained the ability to move some of their extremities independently. We have also seen patients with uncontrolled diabetes with hypertension who now have blood pressures and hemoglobin A1c levels within the normal range as a result of these treatments.

We have also seen great results in patients treated for female/male sexual dysfunction, pain in their joints, neck, and back, and acute stroke (especially when the acute stroke is treated very early to prevent permanent residual symptoms). All patients with autoimmune disorders can also benefit from regenerative medicine; however, they will need continued treatments to maintain the symptoms relief.

Autistic patients in Nigeria are also benefiting from it, especially if the cause is autoimmune related (since up to 25 per cent of the autistic spectrum disorder could be caused by autoimmune diseases). Patients with chronic kidney disease in the early stages are not left out, but they will need more than one treatment session. This is just to mention a few medical conditions. One of the many joys we get is talking to people about their ailments and seeing how regenerative medicine can play a role in rejuvenating their health.

What feedback are you getting from those who have accessed this branch of medicine? Ikudayisi said many of the patients treated at Centre are delighted at their results, so much so that they are spreading the word person to person. We get a great number of them who are so pleasantly surprised of the outcome, as they also see improvements in areas they did not even think to mention to us. It is noteworthy that the therapeutic benefits they have received from regenerative medicine had been practically impossible with conventional medicine hence their satisfaction, joy, and excitement, he said.

The physician said an example is the case of a man with left testicular atrophy and low testosterone. After one session of autologous treatment, the left testicle grew back to normal size and the production of testosterone significantly increased. People who have infertility issues, both male and female, should not give up without considering one of the regenerative medicine protocols, especially those women that have tried In Vitro Fertilisation (IVF) without success, he said.

How affordable is this new branch of medicine? It is truly relatively expensive due to the demand on medical manpower and the present cost of required materials. However, the costs are gradually coming down which we hope is sustained and accelerated so that more people can benefit. Our goal is to get these treatments to as many people as possible. This involves finding ways to reduce cost without compromising on value. Whenever possible, we notify our patients of these price cuts. Furthermore, there are alternative options of treatment with varying costs: this makes these treatments ultimately accessible to more people. The latest biggest price reduction is for people with pain in their peripheral joints, female and male sexual dysfunction, female urinary incontinence, chronic non-healing wounds, facial acne, and uneven skin tone.

I would like to mention that middle class to low income patients in Nigeria have also benefited from some of our regenerative medicine protocols.

Regardless of the cost of the procedure, you cannot put a price tag on a human life. Human life is priceless. As the famous adage goes, Your health, your wealth.

What is the success rate of regenerative medicine for those who have accessed treatment? Ikudayisi said the United States of America (USA) Atlanta-based Emory Healthcare claims that 75 to 80 per cent of patients have had significant pain relief and improved function. The USA Mayo Clinic website says that 40 to 70 per cent of patients find some level of pain relief using some of the regenerative medicine protocols.

The physician said the success rate has been generally high both in the USA and Nigeria at all the centres where he worked. He insisted the results differ from one patient to another, and some other centers do have low success rates. I too have had a couple of patients with delayed onset of effectiveness of treatment or patients needing additional or second treatment sessions before they begin to see positive results. It is important to mention or remind ourselves that there is no guarantee in medicine despite the hype surrounding adult stem cell therapy or regenerative medicine as a whole. It does not work 100 percent of the time. Nonetheless, there is a very high success rate amongst the patients with non-bleeding acute stroke when treatment is done within a couple of days to few weeks, with the goal of preventing permanent residual symptoms post stroke. This was evident in all our non-haemorrhagic acute stroke patients that we treated directly at our facility or through consultation in other hospitals, ranging from a top government official to a low-income grandmother. The general rule of thumb is that the earlier the treatment is given in acute injuries, the higher the success rate, Ikudayisi said.

Excerpt from:
How regenerative medicine could be used to contain COVID-19, others - Guardian

The Induced Pluripotent Stem Cells Market To Witness Fierce Competition Amongst The Key Players – KYT24

Market Report Summary

For Full Information -> Click Here

Read Full Press Release Below

The healthcare industry has been focusing on excessive research and development in the last couple of decades to ensure that the need to address issues related to the availability of drugs and treatments for certain chronic diseases is effectively met. Healthcare researchers and scientists at the Li Ka Shing Faculty of Medicine of the Hong Kong University have successfully demonstrated the utilization of human induced pluripotent stem cells or hiPSCs from the skin cells of the patient for testing therapeutic drugs.

The success of this research suggests that scientists have crossed one more hurdle towards using stem cells in precision medicine for the treatment of patients suffering from sporadic hereditary diseases. iPSCs are the new generation approach towards the prevention and treatment of diseases that takes into account patients on an individual basis considering their genetic makeup, lifestyle, and environment. Along with the capacity to transform into different body cell types and same genetic composition of the donors, hiPSCs have surfaced as a promising cell source to screen and test drugs.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/17968

Company Profile

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/17968

In the present research, hiPSC was synthesized from patients suffering from a rare form of hereditary cardiomyopathy owing to the mutations in Lamin A/C related cardiomyopathy in their distinct families. The affected individuals suffer from sudden death, stroke, and heart failure at a very young age. As on date, there is no exact treatment available for this condition.

This team in Hong Kong tested a drug named PTC124 to suppress specific genetic mutations in other genetic diseases into the iPSC transformed heart muscle cells. While this technology is being considered as a breakthrough in clinical stem cell research, the team at Hong Kong University is collaborating with drug companies regarding its clinical application.

The unique properties of iPS cells provides extensive potential to several biopharmaceutical applications. iPSCs are also used in toxicology testing, high throughput, disease modeling, and target identification. This type of stem cell has the potential to transform drug discovery by offering physiologically relevant cells for tool discovery, compound identification, and target validation.

A new report by Persistence Market Research (PMR) states that the globalinduced pluripotent stem or iPS cell marketis expected to witness a strong CAGR of 7.0% from 2018 to 2026. In 2017, the market was worth US$ 1,254.0 Mn and is expected to reach US$ 2,299.5 Mn by the end of the forecast period in 2026.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/17968

Customization to be the Key Focus of Market Players

Due to the evolving needs of the research community, the demand for specialized cell lines have increased to a certain point where most vendors offering these products cannot depend solely on sales from catalog products. The quality of the products and lead time can determine the choices while requesting custom solutions at the same time. Companies usually focus on establishing a strong distribution network for enabling products to reach customers from the manufacturing units in a short time period.

Entry of Multiple Small Players to be Witnessed in the Coming Years

Several leading players have their presence in the global market; however, many specialized products and services are provided by small and regional vendors. By targeting their marketing strategies towards research institutes and small biotechnology companies, these new players have swiftly established their presence in the market.

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish Kolte Persistence Market Research Address 305 Broadway, 7th FloorNew York City, NY 10007 United States U.S. Ph. +1-646-568-7751 USA-Canada Toll-free +1 800-961-0353 Sales[emailprotected] Website https://www.persistencemarketresearch.com

See the original post:
The Induced Pluripotent Stem Cells Market To Witness Fierce Competition Amongst The Key Players - KYT24

at ASH: Fauci fireside chat, latest on cell therapies, repairing immune function, COVID and clots and more – Fred Hutch News Service

SEATTLE Nov. 18, 2020 Fred Hutchinson Cancer Research Centers latest findings on cell therapies, repairing immune function, and more will be featured at the 62nd American Society of Hematology Annual Meeting & Exposition, to be held virtually Dec. 5 8.

Dr. Stephanie Lee, ASH president and Fred Hutch physician-scientist will kick off the meeting with a fireside chat with Dr. Anthony Fauci. She will also chair ASHs annual E. Donnall Thomas Lecture, named for the Hutchs Nobel laureate Dr. Thomas, who would have turned 100 this year. This lectureship recognizes pioneering research achievements.

Lee shared other meeting highlights:

Follow Lee on Twitter: @StephanieLeeMD.

See below for selected presentations by Fred Hutch researchers, along with Fred Hutch experts to follow on Twitter. Presentations times are in the Pacific time zone.

Reporters requesting additional information or interviews, contact Molly McElroy: mwmcelro@fredhutch.org,206.941.8146 (cell). For media registration for the conference, see the ASH newsroom.

REPAIRING IMMUNE FUNCTION

Damage-Induced Pyroptotic Cell Death Facilitates Regeneration of the Thymus

As a small but mighty butterfly shaped gland in the chest, the thymus is the training ground for T cells to mature into disease-killing machines in the body. But over time, the thymus wears out from stress, infection and age. Finding ways to help repair it could have broad implications for preventing and treating cancer. Dr. Sinead Kinsella, a researcher in the lab of Dr. Jarrod Dudakov, will present findings on a new way of thymus regeneration in which a cell death process called pyroptosis is critical in releasing large numbers of signaling molecules that can trigger the thymus to repair itself. Abstract No. 735 (oral presentation) Monday, Dec. 7, 2020: 2:45 p.m. On Twitter: Dr. Sinead Kinsella: @shinkinsella Dr. Jarrod Dudakov: @Dudakov_lab

T CELL RECEPTOR THERAPY

The immune system plays a key role in detecting tumor antigens and killing cancer cells. But immune response to tumor antigens varies and is often insufficient to prevent tumor growth and relapse. Fred Hutch physician-scientists have identified specific tumor antigens that can be targeted to trigger a potent immune response. The team is creating immunotherapy using genetically modified T cells, called TCR T-cell immunotherapy, to augment these responses in patients.

Phase I Study of Adoptive Immunotherapy with HA-1-Specific CD8+ and CD4+ Memory T Cells for Children and Adults with Relapsed Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation (HCT): Trial in Progress Dr. Elizabeth Krakowwill present a Phase I trial in progress. It uses a T-cell receptor therapy developed byDr. Marie Bleakleyto treat adult and pediatric patients who have relapsed after receiving a stem cell (blood and marrow) transplant for leukemia or other related conditions. Abstract No. 492 (oral presentation) Sunday, Dec. 6, 2020: 2:15 p.m.

A Shared SF3B1 Neoantigen Is Presented on Primary Malignant Cells and Induced Pluripotent Stem Cell-Derived Hematopoietic Lines

Neoantigens, tiny markers that arise from cancer mutations, flag cells as cancerous and could lead to more targeted precision immunotherapies. But, because hundreds of mutations exist on a tumor, targeting the right neoantigen is crucial to trigger an immune response. Dr. Melinda Biernacki, working with the Hutchs Dr. Marie Bleakley, will present findings that identify a specific neoantigen, SF3B1, present in Myelodysplastic Syndromes (MDS), secondary acute myeloid leukemia (AML) and advanced chronic lymphocytic leukemia (CLL), as a promising target for treatment with immunotherapy. Abstract No. 3265 (poster presentation) Monday, Dec. 7, 2020, 7:00 a.m. 3:30 p.m.

CD19 CAR T-CELL THERAPY

Hutch scientists continue to take deep dives into understanding how CD19 CAR T-cell therapy works and how to make it work better for more patients.

Age, performance status, and comorbidities in relation to IEC-associated toxicities (including ICANS) followed by live Q&A panel discussion Scientific Workshop Thursday, Dec. 3, 2020, 2:45 p.m. 3:17 p.m. To be presented by Jordan Gauthier, MD On Twitter: Dr. Jordan Gauthier: @drjgauthier

High IL-15 Serum Concentrations Are Associated with Response to CD19 CAR T-Cell Therapy and Robust In Vivo CAR T-Cell Kinetics Findings by Dr. Jordan Gauthier, a clinician-scholar at Fred Hutch, suggest that high levels of IL-15 could improve CD19 CAR T-cell efficacy and in vivo persistence. Abstract No. 1442 (poster presentation) Saturday, Dec. 5, 2020, 7:00 a.m. 3:30 p.m. ASH Virtual Poster Walk Thursday, Dec. 10, 2020, 7 a.m. On Twitter: Dr. Jordan Gauthier: @drjgauthier

Patient-Reported Outcomes at Time of CAR-T Cell Therapy Abstract No. 3485 (poster presentation) Monday, Dec. 7, 2020, 7:00 a.m. 3:30 p.m. To be presented by Erin Mullane, DNP

CD20 CAR T-CELL THERAPY

Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Researchers at Fred Hutch have developed a CAR T-cell therapy targeting CD20, a specific protein marker in blood cancers, for treating patients with B-cell non-Hodgkin lymphoma who have relapsed or previously been non-responsive to treatment. Dr. Mazyar Shadman will share early results from the ongoing trial taking place at the Seattle Cancer Care Alliance, the Hutchs clinical-care partner. Abstract No. 1443 (poster presentation) Saturday, Dec. 5, 2020, 7:00 a.m. 3:30 p.m. On Twitter: Dr. Mazyar Shadman: @mshadman

CAR T for AML

Therapeutic Targeting of Mesothelin in Acute Myeloid Leukemia with Chimeric Antigen Receptor T Cell Therapy Abstract No. 1959 (poster presentation) Sunday, Dec. 6, 2020, 7:00 a.m. 3:30 p.m. To be presented by Quy Le, PhD

MORE CELL THERAPY

Challenges in Cell Therapy: Relapse and Toxicities Live Q&A Even as a growing number of cancer patients benefit from advances in immunotherapy, relapse and toxic side effects from the treatment remain challenging. Dr. Aude Chapuis will discuss new strategies using genetically modified immune cells to improve the next generation of adoptive T cell therapies in the treatment of solid tumor and blood cancers. Scientific Program, Live Q&A Saturday, December 5, 2020, 9:30 a.m. 10:15 a.m.

PRECISION MEDICINE AND AML

Researchers from the lab ofDr. Soheil Meshinchi, a pediatric oncologist and acute myeloid leukemia specialist, are mapping genetic mutations to how well a patient will respond to various treatments. Their presentations show that ongoing genomic profiling work can help guide targeted treatments for patients with AML, which is the deadliest leukemia among children and young adults.

Genome and Transcriptome Profiling of Monosomy 7 AML Defines Novel Risk and Therapeutic Cohorts Abstract No. 274, (oral presentation) Saturday, Dec. 5, 2020, 2:30 p.m. To be presented by Rhonda E. Ries, MA

Clinical Benefit and Tolerability of Crenolanib in Children with Relapsed Acute Myeloid Leukemia Harboring Treatment Resistant FLT3 ITD and Variant FLT3 TKD Mutations Treated on Compassionate Access Abstract No. 1973, (poster presentation) Sunday, December 6, 2020, 7:00 a.m. 3:30 p.m. To be presented by Katherine Tarlock, MD

Mesothelin Expression Is Associated with Extramedullary Disease and PromotesIn VivoLeukemic Growth in Acute Myeloid Leukemia Abstract No. 1993, (poster presentation) Sunday, Dec. 6, 2020, 7:00 a.m. 3:30 p.m. To be presented by Katherine Tarlock, MD

Target-Informed Repurposing of Immunotherapies in AML a Transcriptome Based Approach for Identifying Immediately Available Therapeutics Abstract No. 2003, (poster presentation) Sunday, Dec. 6, 2020, 7:00 a.m. 3:30 p.m. To be presented by Amanda R. Leonti, MS

BLOOD CLOTS AND CANCER, COVID-19

Dr. Gary Lyman, a medical oncologist, hematologist and public health researcher, has helped develop treatment guidelines for managing blood clots in cancer patients and more recently in COVID-19 patients. His colleagues will present on the COVID-19 findings at this years ASH. Dr. Lyman is available to speak with media. On Twitter: Dr. Gary Lyman: @gary_lyman

Severity of Sars-Cov-2 Infection in Patients with Hematologic Malignancies: A COVID-19 and Cancer Consortium (CCC19) Registry Analysis Abstract No. 1632 (poster presentation) Saturday, Dec. 5, 2020, 7:00 a.m. 3:30 p.m.

Incidence of and Risk Factors for Venous Thromboembolism Among Hospitalized Patients with Cancer and COVID-19: Report from the COVID-19 and Cancer Consortium (CCC19) Registry Abstract No. 204; Session No. 701 (oral presentation) Monday, Dec. 7, 2020: 2:45 PM

HEALTHCARE ECONOMICS

Comparison of Outcomes and Utilization of Therapy in Multiple Myeloma Patients in the USA and Alberta, Canada Abstract No. 2516 (poster presentation) Sunday, Dec. 6, 2020, 7:00 a.m. 3:00 p.m. To be presented by Andrew J. Cowan, MD On Twitter: Dr. Andrew Cowan: @andrewcowanmd Co-author Dr. Veena Shankaran: @ShankaranVeena

CELL BIOLOGY

Distinct Transcriptional signatures distinguish the emergence of multipotent progenitors and hematopoietic stem cells from endothelial precursors in the murine embryo Abstract No. 908, (poster presentation) Saturday, Dec. 5, 2020, 7:00 a.m. 3:30 p.m. To be presented by Tessa Dignum, BS

Note: Scientists at Fred Hutch played a role in developing these discoveries, and Fred Hutch and certain of its scientists may benefit financially from this work in the future.

###

Media Contact: Molly McElroy M:206.941.8146 mwmcelro@fredhutch.org

At Fred Hutchinson Cancer Research Center, home to three Nobel laureates, interdisciplinary teams of world-renowned scientists seek new and innovative ways to prevent, diagnose and treat cancer, HIV/AIDS and other life-threatening diseases. Fred Hutchs pioneering work in bone marrow transplantation led to the development of immunotherapy, which harnesses the power of the immune system to treat cancer. An independent, nonprofit research institute based in Seattle, Fred Hutch houses the nations first National Cancer Institute-funded cancer prevention research program, as well as the clinical coordinating center of the Womens Health Initiative and the international headquarters of the HIV Vaccine Trials Network.

Go here to see the original:
at ASH: Fauci fireside chat, latest on cell therapies, repairing immune function, COVID and clots and more - Fred Hutch News Service

Neurons stripped of their identity are hallmark of Alzheimers disease, study finds – Newswise

Newswise Researchers at the University of California San Diego have identified new mechanisms in neurons that cause Alzheimers disease. In particular, they discovered that changes in the structure of chromatin, the tightly coiled form of DNA, trigger neurons to lose their specialized function and revert to an earlier cell state. This results in the loss of synaptic connections, an effect associated with memory loss and dementia.

The findings are published Nov. 13 in Science Advances.

The study was founded on the question: how do neurons in patients with Alzheimers disease differ from neurons in healthy individuals?

Its a fundamental question that would provide the framework and foundation for understanding Alzheimers disease at the cellular level, and thus pave the path for novel therapeutic approaches, said Shankar Subramaniam, professor of bioengineering at the UC San Diego Jacobs School of Engineering.

Subramaniam worked with an interdisciplinary team of engineers and neuroscientists at UC San Diego to answer this question. They started by taking human induced pluripotent stem cells derived from patients with familial Alzheimers disease, which is a hereditary form of Alzheimers, and transformed them into neurons. They used next generation sequencing techniques to look at what genes are being expressed in these neurons and how gene expression is regulated, and then compared how they differ in neurons of healthy individuals.

They discovered that neurons derived from the patients de-differentiate to a precursor state.

In other words, they cease to be neurons, Subramaniam said. This is the key defect observed across a diversity of patients with distinct mutations. The consequences to the brain are dramatic, with loss of synaptic connections leading to cognitive decline.

The researchers observed other defects: neuronal genes are suppressed, so these cells no longer have any instructions telling them that they are neurons; they are in a precursor-like state, which means they can trigger cell growth and divisionthis is unusual because adult brains do not produce new neurons; and they have inflammation, which signals damage or stress.

The same defects were also observed in post-mortem human brain samples from patients with Alzheimers disease. This was validating for our findings because we werent just seeing these mechanisms in the stem cells, but in actual brain samples as well, Subramaniam said.

The researchers traced all of these mechanisms back to changes in the structure of chromatin. Parts of this structure consist of open regions, where genes are expressed or regulated, and other parts consist of closed regions, where gene expression is repressed. In the diseased neurons, some regions that used to be open are now closed, and vice versa. As a consequence, the neurons are not behaving as they should be, Subramaniam explained.

The team is now working on developing drugs to inhibit these mechanisms.

See the rest here:
Neurons stripped of their identity are hallmark of Alzheimers disease, study finds - Newswise